Bullfrog AI (BFRG) Registration filing summary

Company overview and business model

• bfLEAP is an AI/ML platform licensed from Johns Hopkins University Applied Physics Laboratory, designed to analyze complex preclinical and clinical data and support precision-medicine drug development.

• Strategy combines fee-based analytics and data partnerships with acquiring or licensing drug assets, using patient stratification and clinical development to advance or rescue candidates, then divesting them.

• Revenue channels include contract services, collaborative arrangements with fees and milestone payments, and drug-asset transactions that may include upfront, milestone and royalty payments.

• Licensed programs include mebendazole formulations for cancer and siRNA targeting Beta2-spectrin for liver disease and other indications; the siRNA program was preclinical and BF-223 had positive preclinical results.

• The platform has not yet supported a drug candidate that received approval for commercialization; no pharmaceutical drug clinical trials had been conducted directly as of the filing.

Financial performance and metrics

• H1 2024 revenue was $0; FY2023 revenue was $65,000, compared with $10,000 in FY2022.

• H1 2024 net loss was $3.52M versus $2.81M in H1 2023; loss per share was $0.46 versus $0.51, respectively.

• H1 2024 operating expenses were $3.65M, including $1.07M R&D and $2.58M G&A, versus $2.73M in H1 2023.

• As of June 30, 2024, cash was $5.61M and accumulated deficit was $13.29M; H1 operating cash use was $3.13M.

• Management expected June 30 cash to fund planned operations for ~9 months from the filing absent significant revenue; additional capital would be needed to execute the strategy.

Use of proceeds and capital allocation

• Selling stockholders receive proceeds from registered resales; none go to the issuer. Cash exercise of all registered warrants could yield up to ~$3.26M.

• Any cash warrant-exercise proceeds are intended for general corporate purposes and working capital; management retains broad allocation discretion.

• The October 2024 registered direct offering and concurrent private placement generated ~$3.13M gross proceeds before issuer-paid offering expenses.